KPV — Wolverine Health

How it works

The three C-terminal amino acids of alpha-MSH — responsible for most of its anti-inflammatory activity in cell studies. It blocks NF-κB signalling and reduces pro-inflammatory cytokine production. In animal models of gut inflammation it reduces colitis severity. The oral route interests researchers because IBD affects the gut: if KPV survives digestion, it could hit inflamed tissue directly. That's a big if. Human trials don't exist yet.

FDA status: No FDA approval. Under PCAC July 23–24 2026 review for 503A bulk substance consideration.
WADA status: Permitted in sport
Route: subcutaneous injection; oral (gastrointestinal inflammation research)

Key studies

Alpha-MSH and its C-terminal tripeptide KPV — anti-inflammatory properties — Bhardwaj et al.

KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH, retains the full anti-inflammatory activity of alpha-MSH in keratinocyte models, inhibiting IL-1-stimulated cytokine production.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on KPV

PCAC: The FDA Committee Deciding Whether BPC-157 Stays Legal to Compound

PCAC decided something about BPC-157 in July 2026, and most of the peptide world still can't say what, or what it doesn't mean.

KPV: The Alpha-MSH Fragment With Real Mouse Data and Zero Human Trials

KPV's rodent gut and inflammation data is genuinely coherent. Whether any of that biology survives contact with a human body has never been tested.

KPV: A Real Anti-Inflammatory Signal, an Unproven Skin Case

KPV's gut and immune-cell science is solid. Whether that translates into a working skin-barrier product is the open question nobody's tested yet.

KPV's MC1R Story: A Real Anti-Inflammatory Signal, Zero Human Data

KPV, a three-amino-acid fragment of alpha-MSH, shows a consistent anti-inflammatory signal in cells and mice. No human trial has tested whether that mechanism, or its proposed MC1R selectivity, works the same way in a person.

KPV's Gut-Inflammation Case Rests on One Mouse Trial

KPV, a three-amino-acid fragment of alpha-MSH, quiets inflammatory signalling in cell studies and a single mouse colitis trial. Whether it reaches inflamed human gut tissue, and works there, has never been tested.

503B outsourcing pharmacies and compounded peptides: the regulatory gap that still matters

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

The PCAC review happened July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decided which of seven peptides US compounding pharmacies may eventually dispense by prescription. The recommendation is not an approval, the docket is not all the peptides, and the framing the forums used going in was mostly wrong.

Anti-inflammatory peptides: what calming chronic inflammation could do for you

WADA

Chronic, low-grade inflammation tracks with slower recovery, stiff joints, and how fast you age. Three peptides under FDA review — KPV, BPC-157, and GHK-Cu — each turn it down from a different direction. Here is what that could mean for you, and how far the human proof actually goes.